Excaliard

Isis Pharmaceuticals last month responded to objections about its use of a former executive as an expert in its patent-infringement lawsuit against Santaris Pharma, arguing to the court that a purported conflict of interest does not exist and an order allowing the expert access t

This article has been updated to clarify details regarding Traversa Therapeutics' bankruptcy proceedings.

RXi Pharmaceuticals has completed patient dosing in the second of two phase I trials of its lead drug candidate, the anti-scarring agent RXI-109, and is on track to initiating a phase II study before the end of the year, the company's top executive said last week.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.